Suppr超能文献

静脉血栓形成且纤维蛋白溶解功能缺陷患者的两种不同机制:纤溶酶原激活物浓度低或纤溶酶原激活物抑制剂浓度升高。

Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.

作者信息

Nilsson I M, Ljungnér H, Tengborn L

出版信息

Br Med J (Clin Res Ed). 1985 May 18;290(6480):1453-6. doi: 10.1136/bmj.290.6480.1453.

Abstract

Fibrinolytic components after venous occlusion and concentrations of tissue plasminogen activator inhibitor were studied in 100 consecutive patients with confirmed recurrent deep vein thrombosis or pulmonary embolism. After 20 minutes of venous occlusion the fibrinolytic response was decreased in 33 patients, as measured both amidolytically with S-2251 and on fibrin plates. Two different mechanisms responsible for the poor fibrinolytic response could be distinguished. Twenty two of the patients in whom the response was poor released normal amounts of tissue plasminogen activator antigen, as assayed by immunoradiometric assay, but had appreciably increased concentrations of tissue plasminogen activator inhibitor. The 11 other patients in whom the response was poor had both low tissue plasminogen activator activities and low tissue plasminogen activator antigen concentrations but normal concentrations of tissue plasminogen activator inhibitor. The results show not only that defective synthesis or release of tissue plasminogen activator may be important in the pathogenesis of venous thrombosis but also that a large group of patients with thrombosis have an increased concentration of the inhibitor to tissue plasminogen activator.

摘要

对100例确诊为复发性深静脉血栓形成或肺栓塞的连续患者,研究了静脉闭塞后的纤溶成分及组织型纤溶酶原激活物抑制剂的浓度。静脉闭塞20分钟后,33例患者的纤溶反应降低,这是通过用S - 2251进行酰胺分解测定以及在纤维蛋白平板上测定得出的。可区分出导致纤溶反应不佳的两种不同机制。在纤溶反应不佳的患者中,22例通过免疫放射测定法检测,释放的组织型纤溶酶原激活物抗原量正常,但组织型纤溶酶原激活物抑制剂的浓度明显升高。另外11例纤溶反应不佳的患者,其组织型纤溶酶原激活物活性和组织型纤溶酶原激活物抗原浓度均较低,但组织型纤溶酶原激活物抑制剂浓度正常。结果表明,不仅组织型纤溶酶原激活物的合成或释放缺陷在静脉血栓形成的发病机制中可能很重要,而且一大群血栓形成患者的组织型纤溶酶原激活物抑制剂浓度升高。

相似文献

引用本文的文献

1
3
Chemical Adjustment of Fibrinolysis.纤维蛋白溶解的化学调节
Pharmaceuticals (Basel). 2024 Jan 10;17(1):92. doi: 10.3390/ph17010092.
6
Fibrinolysis and Inflammation in Venous Thrombus Resolution.纤维蛋白溶解与静脉血栓溶解中的炎症反应。
Front Immunol. 2019 Jun 14;10:1348. doi: 10.3389/fimmu.2019.01348. eCollection 2019.

本文引用的文献

8
Clinical relevance of antithrombin III.抗凝血酶III的临床相关性。
Semin Thromb Hemost. 1982 Oct;8(4):276-87. doi: 10.1055/s-2007-1005058.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验